Background: Population-based studies suggest that patients with multiple myeloma (MM) have better outcomes when treated at high-volume facilities, but the relative contribution of provider expertise and hospital resources to improved outcomes is unknown. This study explored how treating facility, individual provider volume, and patient-sharing between MM specialists and community providers influenced outcomes for patients with MM. Patients and Methods: A state cancer registry linked to public and private insurance claims was used to identify a cohort of patients diagnosed with MM in 2006 through 2012. Three multivariable Cox models were used to examine how the following factors impacted overall survival: (1) evaluation at an NCI-designated Comprehensive Cancer Center (NCICCC), (2) the primary oncologist’s volume of patients with MM, and (3) patient-sharing between MM specialists and community oncologists. Results: A total of 1,029 patients diagnosed with MM in 2006 through 2012 were identified. Patients who were not evaluated at an NCICCC had an increased risk of mortality compared with those evaluated at an NCICCC (hazard ratio [HR], 1.50; 95% CI, 1.21–1.86; P<.001). Compared with patients treated by NCICCC MM specialists, those treated by both low-volume community providers (HR, 1.47; 95% CI, 1.14–1.90; P<.01) and high-volume community providers (HR, 1.29; 95% CI, 1.04–1.61; P<.05) had a higher risk of mortality. No difference in mortality was seen between patients treated by NCICCC MM specialists and those treated by the highest-volume community oncologists in the ninth and tenth deciles (HR, 1.08; 95% CI, 0.84–1.37; P=.5591). Patients treated by community oncologists had a higher risk of mortality regardless of patient-sharing compared with patients treated by MM specialists (eg, community oncologist with a history of sharing vs NCICCC MM specialist: HR, 1.49; 95% CI, 1.10–2.02; P<.05). Conclusions: Findings of this study add to the accumulating evidence showing that patients with MM benefit from care at high-volume facilities, and suggest that similar outcomes can be achieved by the highest-volume providers in the community.
Submitted August 24, 2018; accepted for publication March 25, 2019.Author contributions:Study concept: Freeman, Trogdon, Baggett, Tuchman, Shea, Wood. Acquisition of funding: Freeman, Wood. Data curation and analysis: Kuo, Zhou. Methodology: Trogdon, Baggett. Drafting of manuscript: Freeman. Review and editing of manuscript: Freeman, Kuo, Trogdon, Baggett, Tuchman, Shea, Wood.Disclosures: The authors have disclosed that they have not received any financial considerations from any person or organization to support the preparation, analysis, results, or discussion of this article.Funding: This research was supported by a grant from the University Cancer Research Fund.Correspondence: Ashley T. Freeman, MD, BC Cancer – Victoria, 2410 Lee Avenue, Victoria, BC V8R 6V5, Canada. Email: email@example.com
Wolfson J, Can-Lan S, Wyatt L, . Impact of care at NCI comprehensive care centers on outcomes in children, adolescents and young adults with hematologic malignancies [abstract]. Blood 2014;124:Abstract 556.
WolfsonJ, Can-LanS, WyattL, . Impact of care at NCI comprehensive care centers on outcomes in children, adolescents and young adults with hematologic malignancies [abstract]. Blood 2014;124:Abstract 556.)| false
Loberiza FR Jr, Cannon AJ, Weisenburger DD, . Survival disparities in patients with lymphoma according to place of residence and treatment provider: a population-based study. J Clin Oncol 2009;27:5376–5382.
LoberizaFRJr, CannonAJ, WeisenburgerDD, . Survival disparities in patients with lymphoma according to place of residence and treatment provider: a population-based study. J Clin Oncol 2009;27:5376–5382.10.1200/JCO.2009.22.003819752339)| false
GiriS, PathakR, AryalMR, . Impact of hospital volume on outcomes of patients undergoing chemotherapy for acute myeloid leukemia: a matched cohort study. Blood 2015;125:3359–3360.10.1182/blood-2015-01-62576425999448)| false
MesmanR, WestertGP, BerdenBJ, . Why do high-volume hospitals achieve better outcomes? A systematic review about intermediate factors in volume-outcome relationships. Health Policy 2015;119:1055–1067.10.1016/j.healthpol.2015.04.00525958187)| false
Agha L, Ericson KM, Geissler KH, . Team formation and performance: evidence from healthcare referral networks. The National Bureau of Economic Research website. Available at: https://www.nber.org/papers/w24338. Accessed February 1, 2019.
Trogdon JG, Weir WH, Shai S, . Comparing shared patient networks across payers [published online April 3, 2019]. J Gen Intern Med, doi: 10.1007/s11606-019-04978-9
TrogdonJG, WeirWH, ShaiS, . Comparing shared patient networks across payers [published online April 3, 2019]. , doi: 10.1007/s11606-019-04978-9)| false
FaurotKR, Jonsson FunkM, PateV, . Using claims data to predict dependency in activities of daily living as a proxy for frailty. Pharmacoepidemiol Drug Saf 2015;24:59–66.2533547010.1002/pds.3719)| false
United States Census Bureau. Summary File. 2005–2009 American Community Survey. U.S. Census Bureau's American Community Survey Office, 2013. Available at: http://ftp2.census.gov/. Accessed December 4, 2016.
Morrill R, Cromartie J, Hart G. Metropolitan, urban, and rural commuting areas: toward a better depiction of the United States settlement system. Urban Geogr 1999;20:727–748.
MorrillR, CromartieJ, HartG. Metropolitan, urban, and rural commuting areas: toward a better depiction of the United States settlement system. Urban Geogr 1999;20:727–748.10.2747/0272-36184.108.40.2067)| false
Ravindran A, Gonsalves WI, Hashmi SK, . Estimating the annual volume of hematologic cancer cases per hematologist-oncologist in the United States: are we treating rare cancers too rarely? Leuk Lymphoma 2017;58:251–252.
RavindranA, GonsalvesWI, HashmiSK, . Estimating the annual volume of hematologic cancer cases per hematologist-oncologist in the United States: are we treating rare cancers too rarely? Leuk Lymphoma 2017;58:251–252.10.1080/10428194.2016.119385427282880)| false
WarrenJL, HarlanLC, StevensJ, . Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States. J Clin Oncol 2013;31:1984–1989.2356931710.1200/JCO.2012.46.3323)| false
Al-Hamadani M, Hashmi SK, Go RS. Use of autologous hematopoietic cell transplantation as initial therapy in multiple myeloma and the impact of socio-geo-demographic factors in the era of novel agents. Am J Hematol 2014;89:825–830.
Al-HamadaniM, HashmiSK, GoRS. Use of autologous hematopoietic cell transplantation as initial therapy in multiple myeloma and the impact of socio-geo-demographic factors in the era of novel agents. Am J Hematol 2014;89:825–830.2479934310.1002/ajh.23753)| false